{"id":3566,"date":"2022-04-01T20:00:42","date_gmt":"2022-04-01T20:00:42","guid":{"rendered":"https:\/\/linksus.net\/inflectis-ifb-088-earns-orphan-drug-status-als-news-today-als-news-today\/"},"modified":"2022-04-01T20:00:42","modified_gmt":"2022-04-01T20:00:42","slug":"inflectis-ifb-088-earns-orphan-drug-status-als-news-today-als-news-today","status":"publish","type":"post","link":"https:\/\/linksus2.linksus.net\/index.php\/2022\/04\/01\/inflectis-ifb-088-earns-orphan-drug-status-als-news-today-als-news-today\/","title":{"rendered":"InFlectis' IFB-088 Earns Orphan Drug Status \u2013 ALS News Today – ALS News Today"},"content":{"rendered":"

\"\"
Get regular updates to your inbox.
by \t\t\t\t\t\t\t \t\t\t\t\t\t\t\tMarta Figueiredo PhD<\/a> \t\t\t\t\t\t\t<\/span> \t\t\t\t\t\t\t|<\/span> \t\t\t\t\t\t\tIFB-088<\/a> for\u00a0amyotrophic lateral sclerosis<\/a>\u00a0(ALS).
Orphan drug status is given to treatment candidates with the potential to be safe and effective in rare diseases. In the U.S. rare diseases are defined as those affecting fewer than 200,000 people, with no approved treatments, or in cases in which the potential therapy shows significant benefit over existing treatments.
It is meant to expedite IFB-088\u2019s clinical development and review by providing regulatory support and financial benefits. It also provides a seven-year marketing exclusivity period upon regulatory approval, if granted.
\u201cThe granting of [orphan drug designation] reflects the need for new treatment options with new mechanisms of action for patients diagnosed with ALS,\u201d B\u00e9atrice Lejeune, InFlectis<\/a>\u2019 chief regulatory officer, said in a press release<\/a>.
\u201cThis is an important milestone for the company and a significant step forward in our US and European clinical development and regulatory strategy for IFB-088,\u201d Lejeune added.
InFlectis is preparing<\/a> the launch of a Phase 2 clinical trial in France and Italy to test the experimental therapy in people with bulbar-onset ALS<\/a>, which firstly affects a person\u2019s swallowing, chewing, and speech.
\u201cWe are now preparing the setup of clinical operations and planning to enroll the first patient this summer,\u201d said Philippe Gu\u00e9dat, PhD, InFlectis\u2019 founder, president, and CEO.
\u201cWe expect to initiate larger studies in the U.S. and worldwide for the whole ALS population,\u201d Gu\u00e9dat added.
Increasing evidence suggests that sustained cellular stress<\/a> contributes to the accumulation of toxic protein clumps and the development of neurodegenerative diseases such as ALS.
IFB-088, also known as Sephin1 and icerguastat, is a first-in-class orally available small molecule that works by prolonging the integrated stress response (ISR), which is a cellular stress-response mechanism aimed at restoring protein and cellular balance to prevent cell death.
It does so by suppressing an enzymatic complex, called PPP1R15A\/PP1c, specifically in stressed cells, while leaving normal, non-stressed cells unchanged. This is expected to give stressed cells more time to correct their protein imbalances and clear protein aggregates.
IFB-088 is expected have a better safety profile than guanabenz, another suppressor of the PPP1R15A\/PP1c complex that despite showing promising effectiveness in a Phase 2 trial in early ALS, was associated with high rates of adverse events (side effects) and treatment discontinuations.
In that trial, guanabenz was tested in combination with riluzole<\/a> (an approved ALS therapy sold as Rilutek, Tiglutik, or Exservan) in 200 adults with early ALS.
Results showed<\/a> that guanabenz significantly slowed ALS progression, particularly in patients with bulbar onset disease. However, the observed high rates of adverse events, including low blood pressure, and treatment discontinuations, discouraged further development.
Still, these findings demonstrated \u201cthe potential of an ISR modulator to slow the progression of ALS, in particular in bulbar-onset ALS patients,\u201d Lejeune said.
IFB-088 is expected to have a similar efficacy profile without the blood pressure-lowering effects.
Notably, data from a previous Phase 1 trial (NCT03610334<\/a>), involving 72 healthy men, showed that single and multiple ascending doses of IFB-088, ranging from 2.5 mg to 60 mg per day, were generally safe and well-tolerated. No serious adverse events, dose-limiting toxicities, or clinically significant abnormalities were reported.
The upcoming Phase 2 trial will evaluate the safety and effectiveness of adding IFB-088 to riluzole in about 42 people with bulbar-onset ALS. Participants will be assigned randomly to receive an oral capsule of either 50 mg of IFB-088 (28 patients) or a placebo (14 patients), two times a day for six months, in addition to riluzole (100 mg\/day).
Get regular updates to your inbox.
3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com<\/a>
Email: [email protected]<\/span><\/a>
Phone: 1-800-936-1363<\/a>
This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.<\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Get regular updates to your inbox.by Marta Figueiredo PhD | March 31, 2022 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to InFlectis BioScience\u2019s experimental therapy IFB-088 for\u00a0amyotrophic lateral sclerosis\u00a0(ALS).Orphan drug status is given to treatment candidates with the potential to be safe and effective in rare diseases. In the U.S. […]<\/p>\n","protected":false},"author":869,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/3566"}],"collection":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/users\/869"}],"replies":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/comments?post=3566"}],"version-history":[{"count":0,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/3566\/revisions"}],"wp:attachment":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/media?parent=3566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/categories?post=3566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/tags?post=3566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}